Lyon; Jeffrey A.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Lyon; Jeffrey A..The latest application filed is for "system and method for mitigating application layer distributed denial of service attacks using human behavior analysis".

Company Profile

0.10.14

Lyon; Jeffrey A. - Norfolk VA
Lyon; Jeffrey A. - Silver Spring MD
Lyon; Jeffrey A. - Accident MD
Lyon; Jeffrey A. - Sliver Spring MD

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
System and Method for Mitigating Application Layer Distributed Denial of Service Attacks Using Human Behavior Analysis App 20130291107 - Marck; Shawn J. ; et al.	2013-10-31
Isolation and purification of P. falciparum merozoite protein-1.sub.42 vaccine Grant 8,298,546 - Lyon , et al. October 30, 2	2012-10-30
Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide Grant 8,268,615 - Lanar , et al. September 18, 2	2012-09-18
Recombinant P. falciparum merozoite protein-1.sub.42 vaccine Grant 8,211,447 - Angov , et al. July 3, 2	2012-07-03
Isolation and Purification of P. Falciparum Merozoite Protein-142 Vaccine App 20100239614 - Lyon; Jeffrey A. ; et al.	2010-09-23
Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide App 20100040640 - Lanar; David E. ; et al.	2010-02-18
Recombinant P. Falciparum Merozoite Protein-142 Vaccine App 20100028386 - Angov; Evelina ; et al.	2010-02-04
Isolation and purification of P. falciparum merozoite protein-142 vaccine Grant 7,595,191 - Lyon , et al. September 29, 2	2009-09-29
Recombinant P. falciparum merozoite protein-1.sub.42 vaccine Grant 7,563,883 - Angov , et al. July 21, 2	2009-07-21
Expression, purification and uses of a Plasmodium falciparum liver stage antigen 1 polypeptide Grant 7,550,275 - Lanar , et al. June 23, 2	2009-06-23
Recombinant P. falciparum merozoite protein-1 42 vaccine App 20080075741 - Angov; Evelina ; et al.	2008-03-27
Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell App 20080076161 - Angov; Evelina ; et al.	2008-03-27
Recombinant P. falciparum merozoite protein-142 vaccine Grant 7,306,806 - Lyon , et al. December 11, 2	2007-12-11
Recombinant P. falciparum merozoite protein-1.sub.42 vaccine Grant 7,256,281 - Angov , et al. August 14, 2	2007-08-14
Isolation and purification of P. falciparum merozoite protien-142 vaccine App 20060148010 - Lyon; Jeffrey A. ; et al.	2006-07-06
Expression, purification and uses of a Plasmodium falciparum liver stage antigen 1 polypeptide App 20060088547 - Lanar; David E. ; et al.	2006-04-27
Isolation and purification of P. falciparum merozoite protein-142 vaccine Grant 6,855,322 - Lyon , et al. February 15, 2	2005-02-15
Protein expression by codon harmonization and translational attenuation App 20040209323 - Kincaid, Randall L. ; et al.	2004-10-21
Recombinant P. falciparum merozoite protein-142 vaccine App 20040005332 - Angov, Evelina ; et al.	2004-01-08
Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell App 20040005600 - Angov, Evelina ; et al.	2004-01-08
Isolation and purification of P. falciparum merozoite protein-142 vaccine App 20030161838 - Lyon, Jeffrey A. ; et al.	2003-08-28
Recombinant P. falciparum merozoite protein-142 vaccine App 20030161839 - Lyon, Jeffrey A. ; et al.	2003-08-28
Computer-driven amino acid indexer for peptide synthesis Grant 5,243,540 - Van Albert , et al. September 7, 1	1993-09-07

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.